Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zion Pharma Starts US Trial of Treatment for Breast Cancer Brain Metastases

publication date: Sep 9, 2020

Zion Pharma, headquartered in Hong Kong, has started a US Phase I trial of its novel HER2 inhibitor that is designed to address brain metastases of HER2+ breast cancer. Founded in 2018, Zion says it uses its DMPK expertise to develop candidates with best-in-class potential to inhibit cancer, especially those that cross the blood-brain barrier. The trial is being conducted at US sites that include the Dana Farber Cancer Institute and the Duke Cancer Institute. Zion has research operations in Shanghai and Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital